Navigation Links
PTEN: the Treg's handbrake

Naturally occurring CD4+CD25+ Tregs are a specialized subpopulation of T cells that function to prevent other T cells destroying self-tissues. But harnessing the therapeutic potential of Tregs -- for example, to treat autoimmune diseases such as diabetes and rheumatoid arthritis -- is hampered by problems generating sufficient cells to be therapeutically effective. This is because, unlike non-regulatory T cells, Tregs do not proliferate in vitro when stimulated through either their TCR or IL-2 receptor alone.

Now, in a study appearing online on August 17 in advance of print publication in the September issue of the Journal of Clinical Investigation, Laurence Turka and colleagues from the University of Pennsylvania have shown that Tregs from mice with T cells that lack phosphatase and tensin homolog (PTEN) proliferate in response to IL-2. Importantly, PTEN-deficient Tregs retained their suppressive function in vitro and in vivo, indicating that loss of PTEN by Tregs only affects their proliferative capabilities in response to IL-2 and not their other functions. These results identify PTEN as a key protein that regulates the lack of responsiveness of Tregs to IL-2 and could provide researchers with a way to overcome one of the biggest obstacles to harnessing their therapeutic potential.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. NHGRI targets 12 more organisms for genome sequencing
2. NHGRI Selects 13 More Organisms for Genome Sequencing
3. NHGRI expands effort to revolutionize sequencing technologies
4. NHGRI announces new sequencing targets
5. NHGRI aims to make DNA sequencing faster, more cost effective
6. Wiley announces publication of Databasing the Brain
7. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
8. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
9. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
10. GlycoFi announces the first production of antibodies with human glycosylation in yeast
11. CHAVI announces international search for genes affecting HIV response
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: